Overview

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This extension study will enroll subjects who have completed 12 weeks of treatment in Study ALT-801-105. It is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).
Phase:
Phase 1
Details
Lead Sponsor:
Altimmune, Inc.